A report part funded by The Cure Parkinson's Trust assesses the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discusses the advances in our understanding of the role of alpha-synuclein in Parkinson’s and current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications.

Read the full report here: ncbi.nlm.nih.gov/pubmed/28803412